Company intelligence / Profile preview
Pin Siang Medical Biotechnology
Taipei City, Taipei City, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Pin Siang Medical Biotechnology sponsored a randomized, open-label, active-controlled clinical trial comparing Roty F.C. Tablets 10mg to Crestor 10mg F.C. Tablets in patients with hypercholesterolemia to assess efficacy and safety in lowering LDL cholesterol. The status of this trial is listed as "Unknown," and no published results are available. There is no evidence of other ongoing or completed clinical programs.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculeGeneric drug development
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Pin Siang Medical Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pin Siang Medical Biotechnology.